Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SUCNR1 | Q9BXA5 | 4/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22460490 | 0.90 | CTSK (0.52) | CTSKMEN1KMT2AGAASUCNR1 | |
| SCHEMBL22460495 | 0.90 | CTSK (0.52) | CTSKMEN1KMT2AGAASUCNR1 | |
| SCHEMBL24573422 | 0.89 | CTSK (0.49) | CTSKMMP1MMP3MMP9MEN1 | |
| SCHEMBL22460493 | 0.89 | CTSK (0.49) | CTSKMMP1MMP3MMP9MEN1 | |
| SCHEMBL22460455 | 0.86 | CTSK (0.45) | CTSKMMP1MMP3MMP9MEN1 | |
| SCHEMBL22460454 | 0.86 | CTSK (0.45) | CTSKMMP1MMP3MMP9MEN1 | |
| SCHEMBL22460625 | 0.85 | CTSK (0.44) | CTSKMEN1KMT2AGAANPSR1 | |
| SCHEMBL22460624 | 0.85 | CTSK (0.44) | CTSKMEN1KMT2AGAANPSR1 | |
| SCHEMBL19983343 | 0.83 | CTSK (0.46) | CTSKMEN1KMT2ANPSR1MAPT | |
| SCHEMBL19983282 | 0.83 | CTSK (0.62) | CTSKTDP1PAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204457-A1 | ARGININE GINGIPAIN INHIBITORS | CORTEXYME INC (US) | 2022-06-30 | — | — | US | disclosed |
| WO-2020191348-A1 | ARGININE GINGIPAIN INHIBITORS | Cortexyme, Inc. (US) | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204457-A1 | ARGININE GINGIPAIN INHIBITORS | ARGLU1, PADI1, ARG1 | CTSK 2026/4885MMP1 786/4885MMP3 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.